Profitability Highlights

• Reduction in probability of FDA recall due to excessive aggregation as well as failed temperature storage / shipping conditions
• Meritorious patent extension and enhancement
• Redeployment of shelved unstable protein drug target assets
• Expedited existing product enhancement using current inventories
• Enhanced bio-availability